An arthritis drug discovered through AI may simply lower the threat of other seniors dying from COVID-19, according to a new study.
The single daily taking drug, called baricitinib, was first known as a prospective remedy for the virus through BenevolentAI, a London-based startup.
The company has used its synthetic intelligence software to explore clinical literature for drugs that can block the infection process. The most promising remedy discovered was baricitinib, which he said could prevent the infection from entering lung cells.
The new has now demonstrated the protection and efficacy of the drug in the largest patient organization published to date.
[Read: Neural Market Perspectives for Artificial Intelligence in 2021 and Beyond]
Scientists from Imperial College London and the Swedish Karolinska Institute administered baricitinib to 83 patients with COVID-19 with an average age of those being treated in hospitals in Italy and Spain.
They found that patients receiving baricitinib had 71% relief in mortality compared to the other 83 people in the organization who had not taken the drug.
In addition, only 17% of patients receiving baricitinib died or needed a respirator, and 35% of patients who received only popular care.
The study suggests that the drug can damage organs caused by inflammation and prevent the virus from entering human cells.
“We urgently want to locate more effective remedies for COVID-19 until a vaccine is widely available,” said Professor Justin Stebbing of Imperial, co-director of the study. “This is one of the first COVID-19 remedies to be transferred from pc to clinic and laboratory. “
The effects have been subjected to large-scale clinical trials lately. You can read the article in the journal Science Advances.
Thank you!